FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO:14:195 | Real-world effectiveness of anifrolumab in achieving treatment targets and reducing systemic lupus erythematosus disease burden: 6-month interim analysis of the REVEAL study Chiara Cardelli1|2, Chiara Tani1, Luca Moroni3, Filippo Vesentini4, Francesca Bottazzi5, Micaela Fredi6, Ettore Silvagni7, Matteo Piga8, Flavia Riccio9, Fulvia Ceccarelli10, Ginevra De Marchi11, Edoardo Biancalana12, Gianluca Moroncini13, Rita Mulè14, Mariele Gatto15, Laura Coladonato16, Paola Conigliaro17, Maria Gerosa18, Andrea Picchianti Diamanti19, Benedetta Bianchi20, Federica Maiolini20, Michela Gasparotto20, Serena Guiducci20, Maria Ilenia De Andres20, Alberto Lo Gullo20, Silvia Noviello20, On Behalf Of The Reveal Investigators20, Marta Mosca1. | 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa; 2Department of Medical Biotechnologies, University of Siena, Siena; 3Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milano; 4Rheumatology Unit, Department of Medicine, University of Padua, Padova; 5Department of Internal Medicine and Therapeutics, University of Pavia, Pavia; 6Rheumatology and Clinical Immunology, Department of Clinical and Experimental Sciences, University of Brescia, Brescia; 7Section of Rheumatology, Department of Medical Sciences, University of Ferrara; AOU Sant'Anna, Ferrara; 8Rheumatology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari; 9Department of Precision Medicine, University of Campania Luigi Vanvitelli, Napoli; 10Rheumatology Unit, Dept. of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Roma; 11Division of Rheumatology, Department of Medicine, Azienda Sanitaria Universitaria del Friuli Centrale, Udine; 12Internal Interdisciplinary Medicine Unit, Department of Experimental and Clinical Medicine, University of Florence, Firenze; 13Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona; 14Azienda Ospedaliero-Universitaria di Bologna, Internal Medicine and Rheumatology, IRCCS S. Orsola Malpighi, Bologna; 15Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin; AO Mauriziano, Torino; 16Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari; 17Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University of Rome, Roma; 18Clinical Rheumatology, ASST Gaetano Pini CTO; Department of Clinical Sciences and Community Health, University of Milano, Milano; 19Department of Clinical and Molecular Medicine, Sapienza University of Rome; AOU Sant'Andrea, Roma, Italy; 20Italian REVEAL Study Group Italy, Italy
101 -
PO:32:176 | Outcomes of upfront combination vs monotherapy with rituximab or mycophenolate mofetil for systemic sclerosis interstitial lung disease: results from a European Scleroderma Trials and Research cohort study Devis Benfaremo1, Corrado Campochiaro2, Gábor Kumánovics3, Christina Bergmann4, Elisabetta Zanatta5, David Launay6, Serena Guiducci7, Mickael Martin8, Carolina De Souza Müller9, Carlomaurizio Montecucco10, Luc Mouthon11, Gabriella Szucs12, Kastriot Kastrati13, Marie-Elise Truchetet14, Madelon Vonk15, Francesco Del Galdo16, Marco Matucci-Cerinic2, Gianluca Moroncini1, Yannick Allanore17. | 1Department of Clinical and Molecular Sciences, Marche Polytechnic University, Marche University Hospital, Ancona, Italy; 2Vita-Salute San Raffaele University, San Raffaele Hospital, Milano, Italy; 3University of Pécs, Department Of Rheumatology And Immunology, Pécs, Hungary; 4University Hospital Erlangen, Department Internal Medicine 3, Erlangen, Germany; 5Padova University Hospital, Rheumatology Unit, Padova, Italy; 6Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Lille, France; 7University of Florence, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy; 8Poitiers University Hospital, Department of Internal Medicine Poitiers France; 9Hospital de Clinicas da Universidade Federal do Parana Curitiba Brazil; 10Università di Pavia e IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy; 11Hôpital Cochin, Department of Internal Medicine, Paris, France; 12University of Debrecen, Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary; 13Medical University of Vienna, Department of Medicine III, Division of Rheumatology, Vienna, Austria; 14CHU de Bordeaux, Rheumatology department, Bordeaux, France; 15Radboudumc, Department of Rheumatology Nijmegen The Netherlands; 16Leeds Raynauds and Scleroderma Program, NIHR Biomedical Research Centre, Leeds, United Kingdom; 17Université Paris Cité, Cochin Hospital, Rheumatology Department, Paris, France.
89 -
PO:01:004 | Real-world retention of IL-17 inhibitors in psoriatic arthritis: impact of prior IL-17 exposure across multiple treatment lines in the “BIRRA” multicentre cohort Valentino Paci1, Alarico Ariani2, Eleonora Celletti3, Alberto Lo Gullo4, Camilla Mazzanti5, Valeria Nucera6, Natalia Mansueto7, Rosalba Caccavale8, Patrizia Del Medico9, Antonella Farina10, Palma Scolieri11, Cecilia Giampietro12, Olga Addimanda13, Riccardo Bixio14, Maddalena Larosa15, Viviana Ravagnani16, Federica Lumetti17, Aldo Biagio Molica Colella17, Elena Bravi17, Rosetta Vitetta17, Bernd Raffeiner17, Gilda Sandri18, Rosario Foti19, Simone Parisi20, Michele Maria Luchetti Gentiloni1, Gianluca Moroncini1. | 1Clinical Medicine, Department of Clinical and Molecular Sciences, Marche Polytechnic University, AOU delle Marche, Ancona, Italy; 2Internal Medicine and Rheumatology Unit, University Hospital of Parma, Parma, Italy; 3Rheumatology Unit, Clinica Medica Institute, Ospedale SS. Annunziata di Chieti, G.d'Annunzio University of Chieti, Chieti, Italy; 4Rheumatology Unit, ARNAS Garibaldi di Catania, Catania, Italy; 5Center for the Diagnosis and Therapy of Autoimmune Rheumagological Diseases, Ospedale Santa Rosa, ASL Viterbo Viterbo Italy; 6Rheumatology Outpatient Unit, ASL Novara, Novara, Italy; 7Ambulatori di Reumatologia ASL1 Liguria, Imperia Hospitall Imperia Italy; 8Department of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Polo Pontino, Roma, Italy; 9Rheumatology outpatient clinic - Internal Medicine Unit, Civitanova Marche Hospital, Civitanova Marche, Italy; 10Internal Medicine Unit, Rheumatology outpatient clinic, Ospedale A. Murri di Fermo, Fermo, Italy; 11Department of Medical Specialties, Nuovo Regina Margherita Hospital, Rome, Roma, Italy; 12Rheumatology Outpatient Clinic, Azienda ULSS 6 Euganea, Padova, Padova, Italy; 13Rheumatology Unit, Azienda Unità Sanitaria Locale di Bologna -- Policlinico S.Orsola- AOU di Bologna, Bologna, Italy; 14Rheumatology Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy; 15Division of Rheumatology - Medical Specialties Department, Ospedale La Colletta-Azienda Sanitaria Locale 3, Genova, Italy; 16Rheumatology Unit, Santa Chiara Hospital APSS Trento Italy; 17BIRRA - BIologic Retention Rate in chronic Arthritis - study group, Parma, Italy; 18Rheumatology Unit, University of Modena and Reggio Emilia, Modena, Italy; 19Rheumatology Unit, Policlinico San Marco Hospital, Catania, Italy; 20Rheumatology Department, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
130 -
PO:35:219 | Real-world effectiveness of mepolizumab on gastrointestinal involvement in eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome: a multicentre retrospective study Alessia Gatti1, Francesca Regola1, Giulia Fontana1, Mario Addrea Piga2, Gianluca Moroncini2, Palma Carlucci3, Angelo Vacca3, Paolo Delvino4, Enrico Heffler5, Emanuele Nappi5, Jakub Moll6, Laura Losappio6, Jan Schroeder6, Federica Davanzo7, Roberto Padoan7, Edoardo Conticini8, Paolo Cameli8, Greta Pacini9, Alvise Berti9, Lorenzo Vrola10, Paola Tomietto10, Luca Quartuccio11, Jan Willem Cohen Tervaert12, Sabrina Arnold13, Peter Lamprecht13, Florence Roufosse14, Ilaria Cavazzana1, Franco Franceschini1, Giacomo Emmi15, Paola Toniati1. | 1Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia, Italy, Brescia, Italy; 2Università Politecnica delle Marche and Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy, Ancona, Italy; 3Section of Internal Medicine 'Guido Baccelli', DiMePRe-J, University of Bari 'Aldo Moro', Bari, Italy, Bari, Italy; 4Rheumatology Unit, IRCCS San Gerardo dei Tintori, Monza, Italy Monza Italy; 5Department of Biomedical Sciences, Humanitas University and Personalized Medicine, Asthma and Allergy IRCCS Humanitas, Milano, Italy; 6Division of Allergy and Clinical Immunology, ASST GOM Niguarda, Milan, Italy, Milano, Italy; 7Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy, Padova, Italy; 8University of Siena, Siena, Italy, Siena, Italy; 9Santa Chiara Hospital and University of Trento, Unit of Rheumatology, Trento, Italy Trento Italy; 10UCO Medicina Clinica, ASUGI, Cattinara Teaching Hospital, Trieste, Italy, Trieste, Italy; 11Division of Rheumatology, Department of Medicine DMED, University of Udine, Udine, Italy, Udine, Italy; 12University of Alberta, Edmonton, Alberta, Canada and Maastricht University, Maastricht, The Netherlands Maastricht The Netherlands; 13Department of Rheumatology and Clinical Immunology, University of Lübeck, Lübeck, Germany Lubeck Germany; 14Department of Internal Medicine, Hôpital Universitaire de Bruxelles - Erasme, Université Libre de Bruxelles, Belgium Brussels Belgium; 15Clinical Medicine and Clinical Immunology and Rheumatology Unit Cattinara University Hospital and University of Trieste, Trieste, Italy.
111
1 - 4 of 4 items
